8-K - Assembly Biosciences, Inc. | StockGist

AI Analysis

AI-generated analysis. Always verify with the original filing.

Assembly Biosciences approved the 2026 Corporate Bonus Plan and increased CEO Jason A. Okazaki's bonus target from 60% to 65% of base salary, effective for fiscal year 2026.

Key Takeaways

1Compensation Committee approved 2026 Corporate Bonus Plan effective January 1, 2026, for performance-based cash incentives.

2Plan covers employees starting no later than October 31 of performance period, paid in Q1 following year if employed on payment date.

3CEO bonus target up to 75% of base salary (100% corporate objectives); other executives 30-55%; non-executives up to 28%.

4CEO Jason A. Okazaki's bonus target increased from 60% to 65% of base salary via Amendment No. 1, effective 2026.

5Bonuses range 0-1.5x target based on corporate (financial/operational) and individual objectives achievement.

6Exhibits: 10.1 (2026 Corporate Bonus Plan), 10.2 (Amendment No. 1 to CEO employment agreement).

Current Report Details

Event Type

Management Change

Exhibits Only

Disclosure

Mandatory

Variant

8-K

Items Reported

5.02

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. (e) On March

Management Change

9.01

Financial Statements and Exhibits. (d) Exhibits . 1 | Exhibit Number | | Description | |---|---|---| | 10.1 | | 2026 Corporate Bonus Plan. | | 10.2 | | Amendmen

Exhibits Only

Executive & Director Changes

Jason A. Okazaki

Chief Executive Officer and President

Bonus Target Increase

Effective: 2026-03-24

Approved by Compensation Committee

Exhibits (3)

10.1

EX-10.1

10.2

EX-10.2

8-K